Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Stocchi, F; Vacca, L; Berardelli, A; De Pandis, F; Ruggieri, S
   Long-duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half-life
   MOVEMENT DISORDERS
   
   F. Stocchi et al., "Long-duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half-life", MOVEMENT D, 16(2), 2001, pp. 301-305
2. Jankovic, J; Tan, EK
   Choosing dopamine agonists in Parkinson's disease
   CLINICAL NEUROPHARMACOLOGY
   
   J. Jankovic e E.K. Tan, "Choosing dopamine agonists in Parkinson's disease", CLIN NEUROP, 24(5), 2001, pp. 247-253
3. Reuter, M; Netter, P
   The influence of personality on nicotine craving: A hierarchical multivariate statistical prediction model
   NEUROPSYCHOBIOLOGY
   
   M. Reuter e P. Netter, "The influence of personality on nicotine craving: A hierarchical multivariate statistical prediction model", NEUROPSYCHB, 44(1), 2001, pp. 47-53
4. Kaleli, S; Aydin, Y; Erel, CT; Colgar, U
   Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study
   FERTILITY AND STERILITY
   
   S. Kaleli et al., "Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study", FERT STERIL, 75(4), 2001, pp. 718-723
5. Contin, M; Riva, R; Albani, F; Baruzzi, A
   Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease
   CNS DRUGS
   
   M. Contin et al., "Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease", CNS DRUGS, 14(6), 2000, pp. 439-455
6. Wolffgramm, J; Galli, G; Thimm, F; Heyne, A
   Animal models of addiction: models for therapeutic strategies?
   JOURNAL OF NEURAL TRANSMISSION
   
   J. Wolffgramm et al., "Animal models of addiction: models for therapeutic strategies?", J NEURAL TR, 107(6), 2000, pp. 649-668
7. Allain, H; Destee, A; Petit, H; Patay, M; Schuck, S; Bentue-Ferrer, D; Le Cavorzin, P
   Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease
   EUROPEAN NEUROLOGY
   
   H. Allain et al., "Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease", EUR NEUROL, 44(1), 2000, pp. 22-30
8. Colosimo, C; De Michele, M
   Motor fluctuations in Parkinson's disease: pathophysiology and treatment
   EUROPEAN JOURNAL OF NEUROLOGY
   
   C. Colosimo e M. De Michele, "Motor fluctuations in Parkinson's disease: pathophysiology and treatment", EUR J NEUR, 6(1), 1999, pp. 1-21
9. Mauclaire, L; Loc'h, C; Berthommier, E; Ottaviani, M; Boulanger, HD; Coulon, C; Maziere, B
   New preparation of (I-123) iodolisuride from the 2-tri-n-butylstannalisuride derivative
   NUCLEAR MEDICINE AND BIOLOGY
   
   L. Mauclaire et al., "New preparation of (I-123) iodolisuride from the 2-tri-n-butylstannalisuride derivative", NUCL MED BI, 26(3), 1999, pp. 317-321
10. Montastruc, JL; Rascol, O; Senard, JM
    Treatment of Parkinson's disease should begin with a dopamine agonist
    MOVEMENT DISORDERS
    
    J.L. Montastruc et al., "Treatment of Parkinson's disease should begin with a dopamine agonist", MOVEMENT D, 14(5), 1999, pp. 725-730
11. Cannavo, S; Curto, L; Squadrito, S; Almoto, B; Vieni, A; Trimarchi, F
    Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
    
    S. Cannavo et al., "Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma", J ENDOC INV, 22(5), 1999, pp. 354-359
12. Appel, JB; West, WB; Rolandi, WG; Alici, T; Pechersky, K
    Increasing the selectivity of drug discrimination procedures
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    
    J.B. Appel et al., "Increasing the selectivity of drug discrimination procedures", PHARM BIO B, 64(2), 1999, pp. 353-358
13. Rinne, UK
    Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motoric fluctuations.Longterm study over in years in comparison with L-dopa monotherapy
    NERVENARZT
    
    U.K. Rinne, "Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motoric fluctuations.Longterm study over in years in comparison with L-dopa monotherapy", NERVENARZT, 70, 1999, pp. S19-S25
14. De Vries, P; De Visser, PA; Heiligers, JPC; Villalon, CM; Saxena, PR
    Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    
    P. De Vries et al., "Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats", N-S ARCH PH, 359(4), 1999, pp. 331-338
15. Matuszewich, L; Lorrain, DS; Trujillo, R; Dominguez, J; Putnam, SK; Hull, EM
    Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior witha D-2, but not a 5-HMT1A, antagonist
    BRAIN RESEARCH
    
    L. Matuszewich et al., "Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior witha D-2, but not a 5-HMT1A, antagonist", BRAIN RES, 820(1-2), 1999, pp. 55-62
16. Battistin, L; Bardin, PG; Ferro-Milone, F; Ravenna, C; Toso, V; Reboldi, G
    Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomizeddouble blind parallel group study
    ACTA NEUROLOGICA SCANDINAVICA
    
    L. Battistin et al., "Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomizeddouble blind parallel group study", ACT NEUR SC, 99(1), 1999, pp. 36-42
17. Tesarova, E; Zaruba, K; Flieger, M
    Enantioseparation of semisynthetic ergot alkaloids on vancomycin and teicoplanin stationary phases
    JOURNAL OF CHROMATOGRAPHY A
    
    E. Tesarova et al., "Enantioseparation of semisynthetic ergot alkaloids on vancomycin and teicoplanin stationary phases", J CHROMAT A, 844(1-2), 1999, pp. 137-147
18. LANGE KW
    CLINICAL-PHARMACOLOGY OF DOPAMINE AGONISTS IN PARKINSONS-DISEASE
    Drugs & aging
    
    K.W. Lange, "CLINICAL-PHARMACOLOGY OF DOPAMINE AGONISTS IN PARKINSONS-DISEASE", Drugs & aging, 13(5), 1998, pp. 381-389
19. CLAUS JJ; DEKONING I; VANHARSKAMP F; BRETELER MMB; VOET B; GUTZMANN H; DAHLKE F; VANDERCAMMEN T; HOFMAN A
    LISURIDE TREATMENT OF ALZHEIMERS-DISEASE - A PRELIMINARY PLACEBO-CONTROLLED CLINICAL-TRIAL OF SAFETY AND THERAPEUTIC EFFICACY
    Clinical neuropharmacology
    
    J.J. Claus et al., "LISURIDE TREATMENT OF ALZHEIMERS-DISEASE - A PRELIMINARY PLACEBO-CONTROLLED CLINICAL-TRIAL OF SAFETY AND THERAPEUTIC EFFICACY", Clinical neuropharmacology, 21(3), 1998, pp. 190-195
20. POTTER DE; OGIDIGBEN MJ; CHU TC
    LISURIDE ACTS AT MULTIPLE SITES TO INDUCE OCULAR HYPOTENSION AND MYDRIASIS
    Pharmacology
    
    D.E. Potter et al., "LISURIDE ACTS AT MULTIPLE SITES TO INDUCE OCULAR HYPOTENSION AND MYDRIASIS", Pharmacology, 57(5), 1998, pp. 249-260
21. ONEILL MJ; HICKS CA; WARD MA; CARDWELL GP; REYMANN JM; ALLAIN H; BENTUEFERRER D
    DOPAMINE D-2 RECEPTOR AGONISTS PROTECT AGAINST ISCHEMIA-INDUCED HIPPOCAMPAL NEURODEGENERATION IN GLOBAL CEREBRAL-ISCHEMIA
    European journal of pharmacology
    
    M.J. Oneill et al., "DOPAMINE D-2 RECEPTOR AGONISTS PROTECT AGAINST ISCHEMIA-INDUCED HIPPOCAMPAL NEURODEGENERATION IN GLOBAL CEREBRAL-ISCHEMIA", European journal of pharmacology, 352(1), 1998, pp. 37-46
22. CEJKA J; HORAK Z; PAKHOMOVA S; KRATOCHVIL B; SEDMERA P; HAVLICEK V; CVAK L; JEGOROV A
    SYNTHESIS AND CRYSTAL-STRUCTURE OF PERGOLIDE SULFOXIDE
    Collection of Czechoslovak Chemical Communications
    
    J. Cejka et al., "SYNTHESIS AND CRYSTAL-STRUCTURE OF PERGOLIDE SULFOXIDE", Collection of Czechoslovak Chemical Communications, 63(6), 1998, pp. 803-812
23. EGAN CT; HERRICKDAVIS K; MILLER K; GLENNON RA; TEITLER M
    AGONIST ACTIVITY OF LSD AND LISURIDE AT CLONED 5HT(2A) AND 5HT(2C) RECEPTORS
    Psychopharmacology
    
    C.T. Egan et al., "AGONIST ACTIVITY OF LSD AND LISURIDE AT CLONED 5HT(2A) AND 5HT(2C) RECEPTORS", Psychopharmacology, 136(4), 1998, pp. 409-414
24. LOSCHMANN PA; WULLNER U; HENEKA MT; SCHULZ JB; KUNOW M; WACHTEL H; KLOCKGETHER T
    DIFFERENTIAL INTERACTION OF COMPETITIVE NMDA AND AMPA ANTAGONISTS WITH SELECTIVE DOPAMINE D-1 AND D-2 AGONISTS IN A RAT MODEL OF PARKINSONS-DISEASE
    Synapse
    
    P.A. Loschmann et al., "DIFFERENTIAL INTERACTION OF COMPETITIVE NMDA AND AMPA ANTAGONISTS WITH SELECTIVE DOPAMINE D-1 AND D-2 AGONISTS IN A RAT MODEL OF PARKINSONS-DISEASE", Synapse, 26(4), 1997, pp. 381-391
25. DUSKOVA J; POVYSIL C; SCHREIBER V
    AGNORS IN ESTROGEN-INDUCED AND LISURIDE-INHIBITED AND THYREOIDIN-INHIBITED RAT ANTERIOR-PITUITARY HYPERPLASIA - COMPUTER IMAGE-ANALYSIS ANDNONAUTOMATED AGNOR TYPING
    Analytical and quantitative cytology and histology
    
    J. Duskova et al., "AGNORS IN ESTROGEN-INDUCED AND LISURIDE-INHIBITED AND THYREOIDIN-INHIBITED RAT ANTERIOR-PITUITARY HYPERPLASIA - COMPUTER IMAGE-ANALYSIS ANDNONAUTOMATED AGNOR TYPING", Analytical and quantitative cytology and histology, 19(1), 1997, pp. 55-61
26. ALLAIN H; BENTUEFERRER D
    INTERROGATIONS AND SOLUTIONS CONCERNING PARKINSONS-DISEASE
    La Presse medicale
    
    H. Allain e D. Bentueferrer, "INTERROGATIONS AND SOLUTIONS CONCERNING PARKINSONS-DISEASE", La Presse medicale, 26(19), 1997, pp. 909-915
27. DELEU D; HANSSENS Y
    CURRENT AND EMERGING STRATEGIES IN THE MANAGEMENT OF PARKINSONS-DISEASE - A CRITICAL REAPPRAISAL
    Saudi medical journal
    
    D. Deleu e Y. Hanssens, "CURRENT AND EMERGING STRATEGIES IN THE MANAGEMENT OF PARKINSONS-DISEASE - A CRITICAL REAPPRAISAL", Saudi medical journal, 18(2), 1997, pp. 115-126
28. TASDEMIR M; TASDEMIR S; TAVUKCUOGLU S; FICICIOGLU C
    RECTAL LISURIDE IN HYPERPROLACTINEMIC MEN
    Medical science research
    
    M. Tasdemir et al., "RECTAL LISURIDE IN HYPERPROLACTINEMIC MEN", Medical science research, 25(8), 1997, pp. 557-558
29. MULLER TH; EISING EG; REINERS C; PRZUNTEK H; JACOB M; KUHN W
    2-[I-123]-IODOLISURIDE SPET VISUALIZES DOPAMINERGIC LOSS IN DE-NOVO PARKINSONIAN-PATIENTS - IS IT A MARKER OF STRIATAL PRESYNAPTIC DEGENERATION
    Nuclear medicine communications
    
    T.H. Muller et al., "2-[I-123]-IODOLISURIDE SPET VISUALIZES DOPAMINERGIC LOSS IN DE-NOVO PARKINSONIAN-PATIENTS - IS IT A MARKER OF STRIATAL PRESYNAPTIC DEGENERATION", Nuclear medicine communications, 18(12), 1997, pp. 1115-1121
30. INOUE K; KIRIIKE N; KURIOKA M; FUJISAKI Y; IWASAKI S; YAMAGAMI S
    BROMOCRIPTINE ENHANCES FEEDING-BEHAVIOR WITHOUT CHANGING DOPAMINE METABOLISM
    Pharmacology, biochemistry and behavior
    
    K. Inoue et al., "BROMOCRIPTINE ENHANCES FEEDING-BEHAVIOR WITHOUT CHANGING DOPAMINE METABOLISM", Pharmacology, biochemistry and behavior, 58(1), 1997, pp. 183-188
31. FERNANDEZGUASTI A; RODRIGUEZMANZO G
    8-OH-DPAT AND MALE-RAT SEXUAL-BEHAVIOR - PARTIAL BLOCKADE BY NORADRENERGIC LESION AND SEXUAL EXHAUSTION
    Pharmacology, biochemistry and behavior
    
    A. Fernandezguasti e G. Rodriguezmanzo, "8-OH-DPAT AND MALE-RAT SEXUAL-BEHAVIOR - PARTIAL BLOCKADE BY NORADRENERGIC LESION AND SEXUAL EXHAUSTION", Pharmacology, biochemistry and behavior, 56(1), 1997, pp. 111-116
32. MEERT TF; ROMBOUTS J; VOETEN J; NARANJI F; CLINCKE G
    A SIMPLE, NONINVASIVE METHOD FOR THE MEASUREMENT OF RESERPINE-INDUCEDTREMOR IN RATS
    Acta Neurobiologiae Experimentalis
    
    T.F. Meert et al., "A SIMPLE, NONINVASIVE METHOD FOR THE MEASUREMENT OF RESERPINE-INDUCEDTREMOR IN RATS", Acta Neurobiologiae Experimentalis, 57(1), 1997, pp. 75-81
33. FERRARI F; GIULIANI D
    INVOLVEMENT OF DOPAMINE D-2 RECEPTORS IN THE EFFECT OF COCAINE ON SEXUAL-BEHAVIOR AND STRETCHING-YAWNING OF MALE-RATS
    Neuropharmacology
    
    F. Ferrari e D. Giuliani, "INVOLVEMENT OF DOPAMINE D-2 RECEPTORS IN THE EFFECT OF COCAINE ON SEXUAL-BEHAVIOR AND STRETCHING-YAWNING OF MALE-RATS", Neuropharmacology, 36(6), 1997, pp. 769-777
34. ANTKIEWICZMICHALUK L; ROMANSKA I; VETULANI J
    CA2-ACID DIETHYLAMIDE-INDUCED CHANGES IN DOPAMINE AND SEROTONIN METABOLISM( CHANNEL BLOCKADE PREVENTS LYSERGIC)
    European journal of pharmacology
    
    L. Antkiewiczmichaluk et al., "CA2-ACID DIETHYLAMIDE-INDUCED CHANGES IN DOPAMINE AND SEROTONIN METABOLISM( CHANNEL BLOCKADE PREVENTS LYSERGIC)", European journal of pharmacology, 332(1), 1997, pp. 9-14
35. CALDWELL MA; REYMANN JM; ALLAIN H; LEONARD BE; BENTUEFERRER D
    LISURIDE PREVENTS LEARNING AND MEMORY IMPAIRMENT AND ATTENUATES THE INCREASE IN EXTRACELLULAR DOPAMINE-INDUCED BY TRANSIENT GLOBAL CEREBRAL-ISCHEMIA IN RATS
    Brain research
    
    M.A. Caldwell et al., "LISURIDE PREVENTS LEARNING AND MEMORY IMPAIRMENT AND ATTENUATES THE INCREASE IN EXTRACELLULAR DOPAMINE-INDUCED BY TRANSIENT GLOBAL CEREBRAL-ISCHEMIA IN RATS", Brain research, 771(2), 1997, pp. 305-318
36. TORUN S; ERDINC O
    SUPPRESSION OF PRIMARY WRITING TREMOR BY LISURIDE - A CASE-REPORT
    European journal of neurology
    
    S. Torun e O. Erdinc, "SUPPRESSION OF PRIMARY WRITING TREMOR BY LISURIDE - A CASE-REPORT", European journal of neurology, 3(1), 1996, pp. 71-74
37. UITTI RJ; AHLSKOG JE
    COMPARATIVE REVIEW OF DOPAMINE-RECEPTOR AGONISTS IN PARKINSONS-DISEASE
    CNS DRUGS
    
    R.J. Uitti e J.E. Ahlskog, "COMPARATIVE REVIEW OF DOPAMINE-RECEPTOR AGONISTS IN PARKINSONS-DISEASE", CNS DRUGS, 5(5), 1996, pp. 369-388
38. BIER D; DUTSCHKA K; KNUST EJ
    RADIOCHEMICAL SYNTHESIS OF [I-123] 2-IODO-LISURIDE FOR DOPAMINE D2-RECEPTOR STUDIES
    Nuclear medicine and biology
    
    D. Bier et al., "RADIOCHEMICAL SYNTHESIS OF [I-123] 2-IODO-LISURIDE FOR DOPAMINE D2-RECEPTOR STUDIES", Nuclear medicine and biology, 23(3), 1996, pp. 373-376
39. GIULIANI D; FERRARI F
    DIFFERENTIAL BEHAVIORAL-RESPONSE TO DOPAMINE D-2 AGONISTS BY SEXUALLYNAIVE, SEXUALLY ACTIVE, AND SEXUALLY INACTIVE MALE-RATS
    Behavioral neuroscience
    
    D. Giuliani e F. Ferrari, "DIFFERENTIAL BEHAVIORAL-RESPONSE TO DOPAMINE D-2 AGONISTS BY SEXUALLYNAIVE, SEXUALLY ACTIVE, AND SEXUALLY INACTIVE MALE-RATS", Behavioral neuroscience, 110(4), 1996, pp. 802-808
40. CALDWELL MA; REYMANN JM; BENTUEFERRER D; ALLAIN H; LEONARD BE
    THE DOPAMINE AGONISTS LISURIDE AND PIRIBEDIL PROTECT AGAINST BEHAVIORAL AND HISTOLOGICAL-CHANGES FOLLOWING 4-VESSEL OCCLUSION IN THE RAT
    Neuropsychobiology
    
    M.A. Caldwell et al., "THE DOPAMINE AGONISTS LISURIDE AND PIRIBEDIL PROTECT AGAINST BEHAVIORAL AND HISTOLOGICAL-CHANGES FOLLOWING 4-VESSEL OCCLUSION IN THE RAT", Neuropsychobiology, 34(3), 1996, pp. 117-124
41. CORDES M; HIERHOLZER J; SCHELOSKY L; SCHRAG A; RICHTER WS; EICHSTADT H; SCHULZE PE; POEWE W; FELIX R
    IODINE-123-IODO-LISURIDE SPECT IN PARKINSONS-DISEASE
    The Journal of nuclear medicine
    
    M. Cordes et al., "IODINE-123-IODO-LISURIDE SPECT IN PARKINSONS-DISEASE", The Journal of nuclear medicine, 37(1), 1996, pp. 22-25
42. FERRARI F; GIULIANI D
    BEHAVIORAL-EFFECTS INDUCED BY THE DOPAMINE D-3 AGONIST 7-OH-DPAT IN SEXUALLY-ACTIVE AND SEXUALLY-INACTIVE MALE-RATS
    Neuropharmacology
    
    F. Ferrari e D. Giuliani, "BEHAVIORAL-EFFECTS INDUCED BY THE DOPAMINE D-3 AGONIST 7-OH-DPAT IN SEXUALLY-ACTIVE AND SEXUALLY-INACTIVE MALE-RATS", Neuropharmacology, 35(3), 1996, pp. 279-284
43. SCHLEUSSNER E; DISTLER W
    TREATMENT OF ANOVULATION WITH ANTIESTROGE NS, PROLACTIN INHIBITORS, CORTICOSTEROIDS AND THYROID-HORMONES
    Der Gynakologe
    
    E. Schleussner e W. Distler, "TREATMENT OF ANOVULATION WITH ANTIESTROGE NS, PROLACTIN INHIBITORS, CORTICOSTEROIDS AND THYROID-HORMONES", Der Gynakologe, 29(4), 1996, pp. 268-277
44. PACCHETTI C; ALBANI G; MARTIGNONI E; GODI L; ALFONSI E; NAPPI G
    OFF PAINFUL DYSTONIA IN PARKINSONS-DISEASE TREATED WITH BOTULINUM TOXIN
    Movement disorders
    
    C. Pacchetti et al., "OFF PAINFUL DYSTONIA IN PARKINSONS-DISEASE TREATED WITH BOTULINUM TOXIN", Movement disorders, 10(3), 1995, pp. 333-336
45. FISCHER PA
    TREATMENT STRATEGIES IN PARKINSONS-DISEASE AFTER A QUARTER-CENTURY EXPERIENCES WITH L-DOPA THERAPY
    Journal of neural transmission. Supplementum
    
    P.A. Fischer, "TREATMENT STRATEGIES IN PARKINSONS-DISEASE AFTER A QUARTER-CENTURY EXPERIENCES WITH L-DOPA THERAPY", Journal of neural transmission. Supplementum, (46), 1995, pp. 381-389
46. PICCOLI F; RIUGGERI RM
    DOPAMINERGIC AGONISTS IN THE TREATMENT OF PARKINSONS-DISEASE - A REVIEW
    Journal of neural transmission. Supplementum
    
    F. Piccoli e R.M. Riuggeri, "DOPAMINERGIC AGONISTS IN THE TREATMENT OF PARKINSONS-DISEASE - A REVIEW", Journal of neural transmission. Supplementum, (45), 1995, pp. 187-195
47. RABEY JM
    2ND-GENERATION OF DOPAMINE AGONISTS - PROS AND CONS
    Journal of neural transmission. Supplementum
    
    J.M. Rabey, "2ND-GENERATION OF DOPAMINE AGONISTS - PROS AND CONS", Journal of neural transmission. Supplementum, (45), 1995, pp. 213-224
48. AHLENIUS S; LARSSON K
    EFFECTS OF THE DOPAMINE D-3 RECEPTOR-LIGAND 7-OH-DPAT ON MALE-RAT EJACULATORY BEHAVIOR
    Pharmacology, biochemistry and behavior
    
    S. Ahlenius e K. Larsson, "EFFECTS OF THE DOPAMINE D-3 RECEPTOR-LIGAND 7-OH-DPAT ON MALE-RAT EJACULATORY BEHAVIOR", Pharmacology, biochemistry and behavior, 51(2-3), 1995, pp. 545-547
49. MIZUNO Y; KONDO T; NARABAYASHI H
    PERGOLIDE IN THE TREATMENT OF PARKINSONS-DISEASE
    Neurology
    
    Y. Mizuno et al., "PERGOLIDE IN THE TREATMENT OF PARKINSONS-DISEASE", Neurology, 45(3), 1995, pp. 13-21
50. AKAI T; OZAWA M; YAMAGUCHI M; MIZUTA E; KUNO S
    COMBINATION TREATMENT OF THE PARTIAL D-2 AGONIST TERGURIDE WITH THE D-1 AGONIST SKF-82958 IN ETHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS
    The Journal of pharmacology and experimental therapeutics
    
    T. Akai et al., "COMBINATION TREATMENT OF THE PARTIAL D-2 AGONIST TERGURIDE WITH THE D-1 AGONIST SKF-82958 IN ETHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS", The Journal of pharmacology and experimental therapeutics, 273(1), 1995, pp. 309-314
51. SUNDARAM H; TURNER JD; STRANGE PG
    CHARACTERIZATION OF RECOMBINANT SEROTONIN 5-HT1A RECEPTORS EXPRESSED IN CHINESE-HAMSTER OVARY CELLS - THE AGONIST [H-3] LISURIDE LABELS FREE RECEPTOR AND RECEPTOR-COUPLED TO G-PROTEIN
    Journal of neurochemistry
    
    H. Sundaram et al., "CHARACTERIZATION OF RECOMBINANT SEROTONIN 5-HT1A RECEPTORS EXPRESSED IN CHINESE-HAMSTER OVARY CELLS - THE AGONIST [H-3] LISURIDE LABELS FREE RECEPTOR AND RECEPTOR-COUPLED TO G-PROTEIN", Journal of neurochemistry, 65(5), 1995, pp. 1909-1916
52. KRAUSE W; REISSMANN F; KUHNE G; SCHOBEL C
    CIRCADIAN PLASMA-LEVEL PROFILE OF LISURIDE IN RATS AND MICE AFTER CONTINUOUS ADMINISTRATION VIA THE DIET
    Arzneimittel-Forschung
    
    W. Krause et al., "CIRCADIAN PLASMA-LEVEL PROFILE OF LISURIDE IN RATS AND MICE AFTER CONTINUOUS ADMINISTRATION VIA THE DIET", Arzneimittel-Forschung, 45-1(1), 1995, pp. 6-10
53. HIERHOLZER J; CORDES M; SCHELOSKY L; RICHTER W; SCHRAG A; POEWE W; SCHULZE PE; SEMMLER W; EICHSTADT H; FELIX R
    BRAIN SPECT WITH I-123 LISURID IN PATIENT S WITH PARKINSONS-DISEASE AND IN CONTROLS
    Nuklearmedizin
    
    J. Hierholzer et al., "BRAIN SPECT WITH I-123 LISURID IN PATIENT S WITH PARKINSONS-DISEASE AND IN CONTROLS", Nuklearmedizin, 34(4), 1995, pp. 141-145
54. MAY CH; GUILARTE TR; WAGNER HN; VOGEL S
    INTRASTRIATAL INFUSION OF LISURIDE - A POTENTIAL TREATMENT FOR PARKINSONS-DISEASE - BEHAVIORAL AND AUTORADIOGRAPHIC STUDIES IN 6-OHDA LESIONED RATS
    Neurodegeneration
    
    C.H. May et al., "INTRASTRIATAL INFUSION OF LISURIDE - A POTENTIAL TREATMENT FOR PARKINSONS-DISEASE - BEHAVIORAL AND AUTORADIOGRAPHIC STUDIES IN 6-OHDA LESIONED RATS", Neurodegeneration, 3(4), 1994, pp. 305-313
55. OBESO JA; GRANDAS F; HERRERO MT; HOROWSKI R
    THE ROLE OF PULSATILE VERSUS CONTINUOUS DOPAMINE-RECEPTOR STIMULATIONFOR FUNCTIONAL RECOVERY IN PARKINSONS-DISEASE
    European journal of neuroscience
    
    J.A. Obeso et al., "THE ROLE OF PULSATILE VERSUS CONTINUOUS DOPAMINE-RECEPTOR STIMULATIONFOR FUNCTIONAL RECOVERY IN PARKINSONS-DISEASE", European journal of neuroscience, 6(6), 1994, pp. 889-897
56. COLOSIMO C; MERELLO M; ALBANESE A
    CLINICAL USEFULNESS OF APOMORPHINE IN MOVEMENT-DISORDERS
    Clinical neuropharmacology
    
    C. Colosimo et al., "CLINICAL USEFULNESS OF APOMORPHINE IN MOVEMENT-DISORDERS", Clinical neuropharmacology, 17(3), 1994, pp. 243-259
57. AMINOFF MJ
    TREATMENT OF PARKINSONS-DISEASE
    Western journal of medicine
    
    M.J. Aminoff, "TREATMENT OF PARKINSONS-DISEASE", Western journal of medicine, 161(3), 1994, pp. 303-308
58. DARMANI NA; MOCK OB; TOWNS LC; GERDES GF
    THE HEAD-TWITCH RESPONSE IN THE LEAST SHREW (CRYPTOTIS-PARVA) IS A 5-HT2-MEDIATED AND NOT A 5-HT1C-MEDIATED PHENOMENON
    Pharmacology, biochemistry and behavior
    
    N.A. Darmani et al., "THE HEAD-TWITCH RESPONSE IN THE LEAST SHREW (CRYPTOTIS-PARVA) IS A 5-HT2-MEDIATED AND NOT A 5-HT1C-MEDIATED PHENOMENON", Pharmacology, biochemistry and behavior, 48(2), 1994, pp. 383-396
59. PULVIRENTI L; KOOB GF
    LISURIDE REDUCES INTRAVENOUS COCAINE SELF-ADMINISTRATION IN RATS
    Pharmacology, biochemistry and behavior
    
    L. Pulvirenti e G.F. Koob, "LISURIDE REDUCES INTRAVENOUS COCAINE SELF-ADMINISTRATION IN RATS", Pharmacology, biochemistry and behavior, 47(4), 1994, pp. 819-822
60. HUSAK M; KRATOCHVIL B; JEGOROV A; STUCHLIK J
    THE CRYSTAL AND MOLECULAR-STRUCTURE OF LISURIDE HYDROGEN MALEATE
    Zeitschrift fur Kristallographie
    
    M. Husak et al., "THE CRYSTAL AND MOLECULAR-STRUCTURE OF LISURIDE HYDROGEN MALEATE", Zeitschrift fur Kristallographie, 209(4), 1994, pp. 363-366
61. FERRARI F; GIULIANI D
    EFFECT ON RAT-FEEDING BEHAVIOR OF 2 SELECTIVE D-2-DOPAMINE AGONISTS
    Physiology & behavior
    
    F. Ferrari e D. Giuliani, "EFFECT ON RAT-FEEDING BEHAVIOR OF 2 SELECTIVE D-2-DOPAMINE AGONISTS", Physiology & behavior, 56(5), 1994, pp. 921-926
62. FERRARI F; GIULIANI D
    THE SELECTIVE D-2-DOPAMINE-RECEPTOR ANTAGONIST ETICLOPRIDE COUNTERACTS THE EJACULATIO-PRAECOX INDUCED BY THE SELECTIVE D-2-DOPAMINE AGONISTSND-919 IN THE RAT
    Life sciences
    
    F. Ferrari e D. Giuliani, "THE SELECTIVE D-2-DOPAMINE-RECEPTOR ANTAGONIST ETICLOPRIDE COUNTERACTS THE EJACULATIO-PRAECOX INDUCED BY THE SELECTIVE D-2-DOPAMINE AGONISTSND-919 IN THE RAT", Life sciences, 55(14), 1994, pp. 1155-1162
63. GILLIN JC; PULVIRENTI L; WITHERS N; GOLSHAN S; KOOB G
    THE EFFECTS OF LISURIDE ON MOOD AND SLEEP DURING ACUTE WITHDRAWAL IN STIMULANT ABUSERS - A PRELIMINARY-REPORT
    Biological psychiatry
    
    J.C. Gillin et al., "THE EFFECTS OF LISURIDE ON MOOD AND SLEEP DURING ACUTE WITHDRAWAL IN STIMULANT ABUSERS - A PRELIMINARY-REPORT", Biological psychiatry, 35(11), 1994, pp. 843-849
64. PULVIRENTI L; KOOB GF
    LISURIDE REDUCES PSYCHOMOTOR RETARDATION DURING WITHDRAWAL FROM CHRONIC INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION IN RATS
    Neuropsychopharmacology
    
    L. Pulvirenti e G.F. Koob, "LISURIDE REDUCES PSYCHOMOTOR RETARDATION DURING WITHDRAWAL FROM CHRONIC INTRAVENOUS AMPHETAMINE SELF-ADMINISTRATION IN RATS", Neuropsychopharmacology, 8(3), 1993, pp. 213-218
65. MARRARI P; BASILEO G; PIANEZZOLA E; BENEDETTI MS
    DETERMINATION OF FCE 23884, A NEW ERGOLENE DERIVATIVE, AND ITS POSSIBLE METABOLITE, THE 6-NORDERIVATIVE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
    Journal of pharmaceutical and biomedical analysis
    
    P. Marrari et al., "DETERMINATION OF FCE 23884, A NEW ERGOLENE DERIVATIVE, AND ITS POSSIBLE METABOLITE, THE 6-NORDERIVATIVE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION", Journal of pharmaceutical and biomedical analysis, 11(4-5), 1993, pp. 393-399
66. SCHWARZSTEIN D; GARCIAPATTERSON A; GIMENEZ G; CALAF J; PUIGDOMINGO M; CAIXAS A; MATIASGUIU X; WEBB SM
    DOPAMINERGIC RESISTANCE IN A CASE OF INVASIVE MACROPROLACTINOMA
    Journal of endocrinological investigation
    
    D. Schwarzstein et al., "DOPAMINERGIC RESISTANCE IN A CASE OF INVASIVE MACROPROLACTINOMA", Journal of endocrinological investigation, 16(6), 1993, pp. 443-447
67. AKAI T; YAMAGUCHI M; MIZUTA E; KUNO S
    EFFECTS OF TERGURIDE, A PARTIAL D2 AGONIST, ON MPTP-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS
    Annals of neurology
    
    T. Akai et al., "EFFECTS OF TERGURIDE, A PARTIAL D2 AGONIST, ON MPTP-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS", Annals of neurology, 33(5), 1993, pp. 507-511
68. ROBLES RG; VILLA E; ANDRES A; MARTINEZ J; RUILOPE LM; SANCHO JM
    NATRIURETIC EFFECTS OF DOPAMINE AGONIST DRUGS IN MODELS OF REDUCED RENAL MASS
    Journal of cardiovascular pharmacology
    
    R.G. Robles et al., "NATRIURETIC EFFECTS OF DOPAMINE AGONIST DRUGS IN MODELS OF REDUCED RENAL MASS", Journal of cardiovascular pharmacology, 22, 1993, pp. 190000088-190000092
69. KRECZYKLEEDORFER B; WAGNER M; BOSCH S; POEWE W
    LONG-TERM FOLLOW-UP OF CONTINUOUS SUBCUTANEOUS APOMORPHINE PUMP TREATMENT IN PATIENTS WITH ADVANCED PARKINSONS-DISEASE
    Nervenarzt
    
    B. Kreczykleedorfer et al., "LONG-TERM FOLLOW-UP OF CONTINUOUS SUBCUTANEOUS APOMORPHINE PUMP TREATMENT IN PATIENTS WITH ADVANCED PARKINSONS-DISEASE", Nervenarzt, 64(4), 1993, pp. 221-225
70. CALLAHAN PM; CUNNINGHAM KA
    DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE IN RELATION TO DOPAMINE-D(2) RECEPTOR FUNCTION IN RATS
    The Journal of pharmacology and experimental therapeutics
    
    P.M. Callahan e K.A. Cunningham, "DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE IN RELATION TO DOPAMINE-D(2) RECEPTOR FUNCTION IN RATS", The Journal of pharmacology and experimental therapeutics, 266(2), 1993, pp. 585-592
71. MIZOKAWA T; AKAI T; NAKADA Y; YAMAGUCHI M; NAKAGAWA H; HASAN S; RETTIG KJ; WACHTEL H
    TERGURIDE AS A NEW ANTI-HYPERPROLACTINEMIC AGENT - CHARACTERIZATION IN RATS AND DOGS IN COMPARISON WITH BROMOCRIPTINE
    Japanese Journal of Pharmacology
    
    T. Mizokawa et al., "TERGURIDE AS A NEW ANTI-HYPERPROLACTINEMIC AGENT - CHARACTERIZATION IN RATS AND DOGS IN COMPARISON WITH BROMOCRIPTINE", Japanese Journal of Pharmacology, 63(3), 1993, pp. 269-278
72. FERRARI F; GIULIANI D
    INFLUENCE OF IDAZOXAN ON THE DOPAMINE D(2) RECEPTOR AGONIST-INDUCED BEHAVIORAL-EFFECTS IN RATS
    European journal of pharmacology
    
    F. Ferrari e D. Giuliani, "INFLUENCE OF IDAZOXAN ON THE DOPAMINE D(2) RECEPTOR AGONIST-INDUCED BEHAVIORAL-EFFECTS IN RATS", European journal of pharmacology, 250(1), 1993, pp. 51-57
73. PAREDES RG; PINA AL; BERMUDEZRATTONI F
    HYPOTHALAMIC BUT NOT CORTICAL GRAFTS INDUCE RECOVERY OF SEXUAL-BEHAVIOR AND CONNECTIVITY IN MEDIAL PREOPTIC AREA-LESIONED RATS
    Brain research
    
    R.G. Paredes et al., "HYPOTHALAMIC BUT NOT CORTICAL GRAFTS INDUCE RECOVERY OF SEXUAL-BEHAVIOR AND CONNECTIVITY IN MEDIAL PREOPTIC AREA-LESIONED RATS", Brain research, 620(2), 1993, pp. 351-355